Meet Mike, Your Generic Biologics Lobbyist
The debate over generic biologics, which some call follow-on biologics, just took an interesting turn. Although the White House budget would give the FDA new funds to approve such drugs, various companies remain frustrated with the lack of a sanctioned FDA-approved pathway, which is needed before copycat versions of these expensive meds can be developed and sold in the US.
So one drugmaker is turning to YouTube to press its point. Late last week, Insmed corraled one of its scientists, Mike Coleman, to offer a researcher’s view of the value of generic biologics. With his low-key, matter-of-fact delivery; youthful demeanor and standard-issue white laboratory coat, Coleman makes for an unusual lobbyist. But Insmed, which has projects under way to develop several generic biologics, is banking on a new ‘educational campaign,’ another way of saying public relations, to influence Washington and the public. So, here’s Mike…
Larry McGee
Is this the same Mike Coleman? 11 months is reported as 8 years experience?
http://www.linkedin.com/pub/5/630/797
Mike Coleman’s Experience
*
Scientist II
Insmed
(Biotechnology industry)
April 2007 — Present (11 months)
Perhaps there is reason to be skeptical of generic claims to equivalence. Innovative companies just ask generic producers to provide the data that supports their claim. If they are confident their products are effective and safe, just show the data.
Ed Silverman
Hi Larry,
I’ve received a copy of Coleman’s resume and it lists employment at two other companies prior to his employment at Insmed. Between 2002 and 2006, it says he worked for a company called SomaLogic, and then briefly worked for SomaLogic before going to Insmed. I also spoke to Dr. Tad Koch, who runs a lab at the University of Colorado at Boulder, where Coleman was a postdoc and he helped fill in some of the info.
The math, however, is a little off - his work experience is more like seven years, but that’s not counting time in Koch’s lab, which to some is still advanced study, but to others may be considered akin to professionally paid work. I won’t make a judgement on that distinction, but his work record does appear to extend beyond 11 months.
I hope this helps and thanks for writing in with that observation. Let’s see if Coleman updates his Linkedin profile.
Regards
ed